These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2523762)

  • 1. GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting.
    Marty M; Droz JP; Pouillart P; Paule B; Brion N; Bons J
    Cancer Chemother Pharmacol; 1989; 23(6):389-91. PubMed ID: 2523762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting.
    Grunberg SM; Stevenson LL; Russell CA; McDermed JE
    J Clin Oncol; 1989 Aug; 7(8):1137-41. PubMed ID: 2526864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group.
    Seynaeve C; Schuller J; Buser K; Porteder H; Van Belle S; Sevelda P; Christmann D; Schmidt M; Kitchener H; Paes D
    Br J Cancer; 1992 Jul; 66(1):192-7. PubMed ID: 1386245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I/II study of the 5-HT3 antagonist GR38032F in the anti-emetic prophylaxis of patients receiving high-dose cisplatin chemotherapy.
    Smith DB; Newlands ES; Rustin GJ; Begent RH; Crawford SM; Bagshawe KD; Carruthers L
    Cancer Chemother Pharmacol; 1990; 25(4):291-4. PubMed ID: 1688516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting.
    Green JA; Watkin SW; Hammond P; Griggs J; Challoner T
    Cancer Chemother Pharmacol; 1989; 24(2):137-9. PubMed ID: 2525078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Gastrointestinal toxicity induced by anticancer drugs--including new antiemetic drugs].
    Sampi K; Taguchi T
    Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 2):922-8. PubMed ID: 2140498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
    Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
    J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy.
    Cheirsilpa A; Ratanatharathorn V; Sinlarat P; Chindavijak K; Lousoontornsiri W; Chakrapee-Sirisuk S; Srimuninimit V
    J Med Assoc Thai; 1994 Apr; 77(4):201-6. PubMed ID: 7844494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.
    Beck TM; Hesketh PJ; Madajewicz S; Navari RM; Pendergrass K; Lester EP; Kish JA; Murphy WK; Hainsworth JD; Gandara DR
    J Clin Oncol; 1992 Dec; 10(12):1969-75. PubMed ID: 1453211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting.
    Marty M
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S41-5. PubMed ID: 2533898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of GR38032F, an antagonist of 5-hydroxytryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting.
    de Haan LD; de Mulder PH; Beex LV; Debruyne FM; Challoner T; de Pauw BE
    Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1383-4. PubMed ID: 2972545
    [No Abstract]   [Full Text] [Related]  

  • 12. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.
    De Mulder PH; Seynaeve C; Vermorken JB; van Liessum PA; Mols-Jevdevic S; Allman EL; Beranek P; Verweij J
    Ann Intern Med; 1990 Dec; 113(11):834-40. PubMed ID: 2146911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis.
    Grunberg SM; Lane M; Lester EP; Sridhar KS; Mortimer J; Murphy W; Sanderson PE
    Cancer Chemother Pharmacol; 1993; 32(4):268-72. PubMed ID: 8324868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis.
    Hesketh PJ; Murphy WK; Lester EP; Gandara DR; Khojasteh A; Tapazoglou E; Sartiano GP; White DR; Werner K; Chubb JM
    J Clin Oncol; 1989 Jun; 7(6):700-5. PubMed ID: 2523957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ondansetron (GR38032) in the prophylaxis of acute and delayed cisplatin-induced emesis.
    Roila F; Bracarda S; Tonato M; Marangolo M; Bella M; Donati D; Cetto G; Del Favero A
    Clin Oncol (R Coll Radiol); 1990 Sep; 2(5):268-72. PubMed ID: 2148109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist.
    Cunningham D; Hawthorn J; Pople A; Gazet JC; Ford HT; Challoner T; Coombes RC
    Lancet; 1987 Jun; 1(8548):1461-3. PubMed ID: 2885454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
    Cubeddu LX; Hoffmann IS; Fuenmayor NT; Finn AL
    N Engl J Med; 1990 Mar; 322(12):810-6. PubMed ID: 1689807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children.
    Hewitt M; McQuade B; Stevens R
    Clin Oncol (R Coll Radiol); 1993; 5(1):11-4. PubMed ID: 8424909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
    Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
    J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.